Abstract
During the early months of the COVID-19 pandemic, mortality associated with the disease declined in the United States. The standard of care for pharmacological interventions evolved during this period as new and repurposed treatments were used alone and in combination. Though these medications have been studied individually, data are limited regarding the relative impact of different medication combinations. The objectives of this study were to evaluate the association of COVID-19-related mortality and observed medication combinations and to determine whether changes in medication-related practice patterns and measured patient characteristics, alone, explain the decline in mortality seen early in the COVID-19 pandemic. A retrospective cohort study was conducted at a multi-hospital healthcare system exploring the association of mortality and combinations of remdesivir, corticosteroids, anticoagulants, tocilizumab, and hydroxychloroquine. Multivariable logistic regression was used to identify predictors of mortality for both the overall population and the population stratified by intensive care and non-intensive care unit admissions. A separate model was created to control for the change in unmeasured variables over time. For all...Continue Reading
References
Mar 24, 2020·American Journal of Respiratory and Critical Care Medicine·Chun PanHaibo Qiu
Mar 29, 2020·Journal of Thrombosis and Haemostasis : JTH·Ning TangZiyong Sun
Apr 21, 2020·Journal of the American College of Cardiology·Behnood BikdeliUNKNOWN Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working
Apr 28, 2020·Journal of Thrombosis and Haemostasis : JTH·Jecko ThachilToshiaki Iba
Apr 29, 2020·Chest·Jared RadbelPinki J Bhatt
May 7, 2020·Annals of Internal Medicine·Dominic WichmannStefan Kluge
May 8, 2020·The New England Journal of Medicine·Joshua GelerisNeil W Schluger
May 11, 2020·Journal of the American College of Cardiology·Ishan ParanjpeGirish N Nadkarni
May 16, 2020·JAMA : the Journal of the American Medical Association·Chiara SartiniAlberto Zangrillo
May 19, 2020·JAMA : the Journal of the American Medical Association·Francis S Collins, Paul Stoffels
May 23, 2020·Annals of Internal Medicine·Holger J SchünemannElie A Akl
Jun 17, 2020·The Lancet Infectious Diseases·UNKNOWN WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection
Jul 2, 2020·JAMA : the Journal of the American Medical Association·Jody W Zylke, Howard Bauchner
Jul 21, 2020·ERJ Open Research·Sofia VidaliGuglielmo Consales
Jul 31, 2020·MMWR. Morbidity and Mortality Weekly Report·Mark W TenfordeUNKNOWN IVY Network Investigators
Aug 1, 2020·Annals of Internal Medicine·Bram RochwergHolger J Schünemann
Sep 3, 2020·JAMA : the Journal of the American Medical Association·Pierre-François DequinUNKNOWN CAPE COVID Trial Group and the CRICS-TriGGERSep Network
Sep 3, 2020·JAMA : the Journal of the American Medical Association·Derek C AngusCharlotte Summers
Oct 21, 2020·JAMA Internal Medicine·Carlo SalvaraniUNKNOWN RCT-TCZ-COVID-19 Study Group
Oct 21, 2020·JAMA Internal Medicine·Olivier HermineUNKNOWN CORIMUNO-19 Collaborative Group
Oct 22, 2020·The New England Journal of Medicine·John H StoneUNKNOWN BACC Bay Tocilizumab Trial Investigators
Dec 11, 2020·JAMA Network Open·Ning RosenthalStella Safo
Dec 29, 2020·The American Journal of the Medical Sciences·Michael LiJesse Roman
Feb 10, 2021·Blood Advances·Adam CukerHolger J Schünemann